Alliance pharmaceutique pancanadienne (APP) – dernières mises à jour

État Nombre total Résumé
En négociation 32 Non liées à l’oncologie : 20
Liées à l’oncologie : 12
Négociations envisagées 17 Non liées à l’oncologie : 6
Liées à l’oncologie : 11
Négociations terminées 882 Avec lettre d’intention : 765
Sans entente : 117
Négociations qui n’ont pas eu lieu 114

Activités de l’APP dans les quatre dernières semaines

Voici les activités des quatre dernières semaines. Veuillez prendre note que le traitement de ces mises à jour peut prendre d’une à deux semaines.

Lettres d’engagement transmises au cours des quatre dernières semaines

Marque Fabricant Indication Date d’engagement
Scemblix Novartis Pharmaceuticals Canada Inc. For the treatment of adult patients with newly diagnosed or previously treated Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) (first line).
Elahere AbbVie Corporation ​For the treatment of adult patients with folate receptor-alpha (FRα) positive*, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.
Columvi Hoffmann-La Roche Ltd. In combination with gemcitabine and oxaliplatin for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are not candidates for autologous stem cell transplant (ASCT).
Voranigo Servier Canada Inc. For the treatment of Grade 2 WHO 2016, 2021 grading system astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and olde
Venclexta AbbVie Corporation In combination with ibrutinib, is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

Négociations achevées dans les quatre dernières semaines avec une lettre d’intention

Marque Fabricant Indication Date d’engagement Date d’achèvement
Myfembree Knight Therapeutics Inc. Management of heavy menstrual bleeding associated with uterine fibroids
Omnipod 5 Insulet Canada Corporation Patients with Type 1 Diabetes aged 2 years and old
Opdivo-Yervoy Bristol Myers Squibb Canada Inc. For the first-line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
Piasky Hoffmann-La Roche Ltd. Paroxysmal nocturnal hemoglobinuria (PNH)
Jemperli GlaxoSmithKline Inc. ​In combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy.
Nubeqa Bayer Inc. For the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
Polivy Hoffmann-La Roche Ltd. In combination with R-CHP for the treatment of adult patients with previously untreated large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high grade B-cell lymphoma, Epstein-Barr virus-positive (E
Stivarga Bayer Inc. For the treatment of metastatic osteosarcoma in patients who received at least 1 prior line of therapy.
Bylvay Medison Pharma Canada Inc. Alagille syndrome
Skyrizi AbbVie Corporation Ulcerative Colitis

Négociations achevées dans les quatre dernières semaines sans entente

Marque Fabricant Indication Date d’engagement Date d’achèvement
Wegovy Novo Nordisk Canada Inc. As an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: 30 kg/m2 or greater (obesity), or 27 kg/m2 or greater (overweight) in the presence of at leas
Pavblu Amgen Canada Inc. Multiple Indications

Négociations que l’APP a décidé de ne pas entreprendre dans les quatre dernières semaines

Marque Fabricant Indication Aucune date de négociation
Lumakras Amgen Canada Inc. Advanced non-small cell lung cancer, KRAS G12C-mutated